Svelte Medical Systems reported that its drug-eluting coronary stent Integrated Delivery System (IDS) for percutaneous coronary intervention (PCI) met all DIRECT II study six-month angiographic and clinical endpoints. 

Mallinckrodt announced the U.S. launch of the OptiSync data management system as a new technology in its Global Medical Imaging segment. 

September 24, 2014 — An initiative to improve the use of cardiac telemetry at Christiana Care Health System enhanced the value of care to patients and resulted in savings of $4.8 million, Christiana Care researchers reported in JAMA Internal Medicine, published online Sept. 22.

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated satisfactory and comparable angiographic and clinical outcomes compared to the two drug-eluting stents (DES). Findings were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of drug eluting stents (DES). 

Capricor Therapeutics Inc. presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation by Raj R. Makker, M.D., of Cedars-Sinai Medical Center, at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference Sept. 16.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now